Titre : Maladie du greffon contre l'hôte

Maladie du greffon contre l'hôte : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Field Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Maladie du greffon contre l'hôte : Questions médicales les plus fréquentes", "headline": "Maladie du greffon contre l'hôte : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Maladie du greffon contre l'hôte : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-17", "dateModified": "2025-05-12", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Maladie du greffon contre l'hôte" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Maladies du système immunitaire", "url": "https://questionsmedicales.fr/mesh/D007154", "about": { "@type": "MedicalCondition", "name": "Maladies du système immunitaire", "code": { "@type": "MedicalCode", "code": "D007154", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Syndrome de bronchiolite oblitérante", "alternateName": "Bronchiolitis Obliterans Syndrome", "url": "https://questionsmedicales.fr/mesh/D000092122", "about": { "@type": "MedicalCondition", "name": "Syndrome de bronchiolite oblitérante", "code": { "@type": "MedicalCode", "code": "D000092122", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C20.452.500" } } } ], "about": { "@type": "MedicalCondition", "name": "Maladie du greffon contre l'hôte", "alternateName": "Graft vs Host Disease", "code": { "@type": "MedicalCode", "code": "D006086", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Stephanie J Lee", "url": "https://questionsmedicales.fr/author/Stephanie%20J%20Lee", "affiliation": { "@type": "Organization", "name": "Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington." } }, { "@type": "Person", "name": "Betty K Hamilton", "url": "https://questionsmedicales.fr/author/Betty%20K%20Hamilton", "affiliation": { "@type": "Organization", "name": "Blood and Marrow Transplant Program, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States of America." } }, { "@type": "Person", "name": "Najla El Jurdi", "url": "https://questionsmedicales.fr/author/Najla%20El%20Jurdi", "affiliation": { "@type": "Organization", "name": "Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis." } }, { "@type": "Person", "name": "Steven Z Pavletic", "url": "https://questionsmedicales.fr/author/Steven%20Z%20Pavletic", "affiliation": { "@type": "Organization", "name": "National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD, United States of America." } }, { "@type": "Person", "name": "Anthony D Sung", "url": "https://questionsmedicales.fr/author/Anthony%20D%20Sung", "affiliation": { "@type": "Organization", "name": "Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "The number of examinations required for the accurate prediction of the progression of the central 10-degree visual field test in glaucoma.", "datePublished": "2022-11-07", "url": "https://questionsmedicales.fr/article/36344722", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-23604-z" } }, { "@type": "ScholarlyArticle", "name": "Assessment of visual field progression in glaucoma.", "datePublished": "2022-11-15", "url": "https://questionsmedicales.fr/article/36378107", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/ICU.0000000000000932" } }, { "@type": "ScholarlyArticle", "name": "Visual Field Defect Patterns Associated With Lesions of the Retrochiasmal Visual Pathway.", "datePublished": "2022-06-14", "url": "https://questionsmedicales.fr/article/36166759", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/WNO.0000000000001601" } }, { "@type": "ScholarlyArticle", "name": "Association of superficial macular vessel density with visual field progression in open-angle glaucoma with central visual field damage.", "datePublished": "2023-05-03", "url": "https://questionsmedicales.fr/article/37137927", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-34000-6" } }, { "@type": "ScholarlyArticle", "name": "Visual fields in glaucoma: Where are we now?", "datePublished": "2023-02-16", "url": "https://questionsmedicales.fr/article/36751125", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ceo.14210" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies du système immunitaire", "item": "https://questionsmedicales.fr/mesh/D007154" }, { "@type": "ListItem", "position": 3, "name": "Maladie du greffon contre l'hôte", "item": "https://questionsmedicales.fr/mesh/D006086" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Maladie du greffon contre l'hôte - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Maladie du greffon contre l'hôte", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-16", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Maladie du greffon contre l'hôte", "description": "Comment diagnostiquer la GVHD ?\nQuels tests sont utilisés pour la GVHD ?\nQuels signes cliniques indiquent la GVHD ?\nLa GVHD peut-elle être confondue avec d'autres maladies ?\nQuel rôle joue l'historique médical dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Visual+Field+Tests&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Maladie du greffon contre l'hôte", "description": "Quels sont les symptômes cutanés de la GVHD ?\nLa GVHD affecte-t-elle le système digestif ?\nQuels symptômes hépatiques sont associés à la GVHD ?\nLa GVHD peut-elle causer des problèmes oculaires ?\nQuels symptômes respiratoires peuvent survenir ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Visual+Field+Tests&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Maladie du greffon contre l'hôte", "description": "Comment prévenir la GVHD après une greffe ?\nLe choix du donneur influence-t-il la GVHD ?\nLes traitements préventifs sont-ils efficaces ?\nLes greffes de cellules souches de sang de cordon sont-elles plus sûres ?\nLes soins post-greffe aident-ils à prévenir la GVHD ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Visual+Field+Tests&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Maladie du greffon contre l'hôte", "description": "Quels traitements sont utilisés pour la GVHD ?\nLa photothérapie est-elle efficace contre la GVHD ?\nLes greffes de cellules souches peuvent-elles aider ?\nQuels médicaments sont prescrits pour la GVHD ?\nLa thérapie cellulaire est-elle une option ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Visual+Field+Tests&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Maladie du greffon contre l'hôte", "description": "Quelles sont les complications de la GVHD ?\nLa GVHD peut-elle entraîner des infections ?\nQuels cancers peuvent survenir après la GVHD ?\nLa GVHD peut-elle affecter la qualité de vie ?\nComment gérer les complications de la GVHD ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Visual+Field+Tests&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Maladie du greffon contre l'hôte", "description": "Quels sont les principaux facteurs de risque de la GVHD ?\nL'âge influence-t-il le risque de GVHD ?\nLe sexe du receveur joue-t-il un rôle ?\nLes antécédents médicaux augmentent-ils le risque ?\nLa source de greffe influence-t-elle le risque ?", "url": "https://questionsmedicales.fr/mesh/D006086?mesh_terms=Visual+Field+Tests&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer la GVHD ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'examen clinique et des biopsies cutanées ou intestinales." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour la GVHD ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des biopsies sont effectués pour évaluer l'atteinte des organes." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent la GVHD ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent éruptions cutanées, diarrhée, et atteinte hépatique." } }, { "@type": "Question", "name": "La GVHD peut-elle être confondue avec d'autres maladies ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut être confondue avec des infections ou d'autres maladies auto-immunes." } }, { "@type": "Question", "name": "Quel rôle joue l'historique médical dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'historique de greffe et les traitements antérieurs sont cruciaux pour le diagnostic." } }, { "@type": "Question", "name": "Quels sont les symptômes cutanés de la GVHD ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des éruptions, des démangeaisons et des desquamations." } }, { "@type": "Question", "name": "La GVHD affecte-t-elle le système digestif ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des diarrhées, des douleurs abdominales et des nausées." } }, { "@type": "Question", "name": "Quels symptômes hépatiques sont associés à la GVHD ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent jaunisse, fatigue et élévation des enzymes hépatiques." } }, { "@type": "Question", "name": "La GVHD peut-elle causer des problèmes oculaires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut entraîner sécheresse oculaire et inflammation conjonctivale." } }, { "@type": "Question", "name": "Quels symptômes respiratoires peuvent survenir ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la toux, l'essoufflement et des infections pulmonaires peuvent apparaître." } }, { "@type": "Question", "name": "Comment prévenir la GVHD après une greffe ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut l'utilisation d'immunosuppresseurs et le choix de donneurs compatibles." } }, { "@type": "Question", "name": "Le choix du donneur influence-t-il la GVHD ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un donneur HLA compatible réduit le risque de GVHD." } }, { "@type": "Question", "name": "Les traitements préventifs sont-ils efficaces ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements préventifs diminuent significativement l'incidence de la GVHD." } }, { "@type": "Question", "name": "Les greffes de cellules souches de sang de cordon sont-elles plus sûres ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent présenter un risque réduit de GVHD par rapport aux greffes de moelle osseuse." } }, { "@type": "Question", "name": "Les soins post-greffe aident-ils à prévenir la GVHD ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi médical rigoureux et des soins appropriés sont essentiels." } }, { "@type": "Question", "name": "Quels traitements sont utilisés pour la GVHD ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des corticostéroïdes et des immunosuppresseurs." } }, { "@type": "Question", "name": "La photothérapie est-elle efficace contre la GVHD ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la photothérapie peut être utilisée pour traiter les éruptions cutanées." } }, { "@type": "Question", "name": "Les greffes de cellules souches peuvent-elles aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des greffes supplémentaires peuvent être envisagées dans certains cas de GVHD sévère." } }, { "@type": "Question", "name": "Quels médicaments sont prescrits pour la GVHD ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des médicaments comme le méthotrexate et la ciclosporine sont souvent prescrits." } }, { "@type": "Question", "name": "La thérapie cellulaire est-elle une option ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la thérapie cellulaire peut être explorée pour des cas réfractaires." } }, { "@type": "Question", "name": "Quelles sont les complications de la GVHD ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent infections, défaillance d'organes et cancers secondaires." } }, { "@type": "Question", "name": "La GVHD peut-elle entraîner des infections ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la GVHD affaiblit le système immunitaire, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels cancers peuvent survenir après la GVHD ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des cancers comme le lymphome et le carcinome peuvent se développer après la GVHD." } }, { "@type": "Question", "name": "La GVHD peut-elle affecter la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes et complications peuvent gravement impacter la qualité de vie." } }, { "@type": "Question", "name": "Comment gérer les complications de la GVHD ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion inclut un suivi médical régulier et des traitements symptomatiques." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque de la GVHD ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, le sexe, et la compatibilité HLA entre donneur et receveur." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque de GVHD ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients plus âgés ont un risque accru de développer la GVHD." } }, { "@type": "Question", "name": "Le sexe du receveur joue-t-il un rôle ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les hommes peuvent avoir un risque plus élevé de GVHD que les femmes." } }, { "@type": "Question", "name": "Les antécédents médicaux augmentent-ils le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies auto-immunes ou de greffes augmentent le risque." } }, { "@type": "Question", "name": "La source de greffe influence-t-elle le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les greffes de moelle osseuse présentent un risque plus élevé que celles de sang de cordon." } } ] } ] }

Sources (10000 au total)

Assessment of visual field progression in glaucoma.

Perimetry plays an important role in the diagnosis and management of glaucoma. This article discusses the assessment of visual field progression in patients with glaucoma.... Selecting the best visual field test strategy and establishing a baseline of visual fields will assist clinicians in the detection of glaucomatous progression. Repeat testing serves to confirm or refu... Many treated patients with glaucoma will experience visual field progression. Optimal utilization of visual field testing strategy and analytical software can help clinicians identify patients with gl...

Visual Field Defect Patterns Associated With Lesions of the Retrochiasmal Visual Pathway.

Perimetry is widely used in the localization of retrochiasmal visual pathway lesions. Although macular sparing, homonymous paracentral scotomas, and quadrantanopias are regarded as features of posteri... Retrospective record review conducted in a single, academic, medical center using an electronic search engine with the terms ""homonymous hemianopia," "optic tract," "temporal lobectomy," "visual fiel... From an original cohort of 256 cases, only 83 had MRI-defined lesions that were limited to particular retrochiasmal segments and had visual field defect patterns that allegedly permitted localization ... In correlating discrete MRI-defined retrochiasmal lesions with visual field defect patterns identified on static perimetry, this study showed that macular sparing, homonymous paracentral scotomas, and...

Humphrey visual field made easy for residents.

Visual field testing is an indispensable part of the assessment of glaucoma. Of paramount importance to both the practitioner and the perimetrist is the guidance on how to conduct the test to get the ... To simplify the basics of understanding single-field analysis of visual field tests by using the Humphrey perimeter.... The general principle and a brief overview of how the Humphrey visual field is conducted and the approach to interpreting the results of single field analysis in an easy-to-understand manner are prese... This educational video is an attempt to simplify the interpretation of Humphrey visual field single-field analysis with illustrations and video clips that would be useful to practicing ophthalmologist... https://youtu.be/x8iZLDR4XdY....

Foveal avascular zone vessel density is associated with visual field progression in early-stage glaucoma eyes with central visual field damage.

We investigated the relationship between foveal avascular zone (FAZ)-related parameters, assessed by optical coherence tomography angiography (OCT-A), and visual field (VF) progression in early-stage ...

Five-Year Visual Field Outcomes of the HORIZON Trial.

To compare visual field (VF) progression between glaucoma patients receiving cataract surgery alone (CS) or with a Hydrus microstent (CS-HMS).... Post hoc analysis of VF data from the HORIZON multicenter randomized controlled trial.... A total of 556 patients with glaucoma and cataract were randomized 2:1 to either CS-HMS (369) or CS (187) and followed up for 5 years. VF was performed at 6 months and then every year after surgery. W... Data from 352 eyes in the CS-HMS arm and 165 in the CS arm were analyzed (2966 VFs). The mean RoP was -0.26 dB/y (95% credible interval -0.36, -0.16) for CS-HMS and -0.49 dB/y (95% credible interval -... CS-HMS has a significant effect on VF preservation in glaucoma patients compared with CS alone, reducing the proportion of fast progressors....

A Consensus Statement on the Terminology for Automated Visual Field Abnormalities.

A multitude of terms have been used to describe automated visual field abnormalities. To date, there is no universally accepted system of definitions or guidelines. Variability among clinicians create... In phase one of the study, all neuro-ophthalmologists in Israel were asked to complete a survey in which they described the abnormalities in 10 selected automated visual field tests. In phase 2 of the... Twenty-six neuro-ophthalmologists participated in the initial survey. On average, there were 7.5 unique descriptions for each of the visual fields (SD 3.17), a description of only the location in 24.6... The study confirmed a great degree of variability in the use of terminology to describe automated visual field abnormalities. The creation of a consensus statement was associated with improved use of ...